Global Antidiarrheals Market Size 2024, Forecast To 2033
23 Jan, 2024
The antidiarrhoeals market has experienced steady growth, increasing from $3.76 billion in 2023 to $3.89 billion in 2024, with a 3.3% CAGR. Historical growth is attributed to disease prevalence, global health initiatives, an aging population, pharmaceutical innovation, and patient awareness. Projections suggest steady growth, reaching $4.41 billion by 2028, with a 3.2% CAGR. The forecasted period attributes growth to emerging markets, environmental factors, global health challenges, and epidemiology and disease burden. Major trends include digital health and telemedicine, patient-centric care, self-care, and over-the-counter (OTC) products, personalized medicine, and biotechnology advancements.
Global Antidiarrheals Market Key Driver
The antidiarrheal drug market is witnessing substantial growth, primarily driven by the increasing number of diarrhea cases, especially among children. UNICEF reports that diarrhea is the second leading cause of death for children under 5, claiming 760,000 lives annually. The rising incidence of diarrhea necessitates a higher demand for antidiarrheal drugs, contributing to the growth of this pharmaceutical market.
Get A Free Sample Of The Global Antidiarrheals Market ReportGlobal Antidiarrheals Market Segments
The antidiarrhoeals market covered in this report is segmented –
1) By Drug Class: Mucosal Protectants, Motility Modifying Drugs
2) By Application: Adults, Childrens
3) By Type: OTC drugs, Prescription Drugs
By Geography: The regions covered in the antidiarrheals market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the antidiarrhoeals market in 2023. The regions covered in the antidiarrhoeals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Antidiarrheals Industry Players
GlaxoSmithKline plc, Actelion Pharmaceuticals Ltd (a subsidiary of Johnson & Johnson), Perrigo Company plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Pfizer Inc., The Procter & Gamble Company, Sanofi-aventis U.S. LLC, Bayer AG, Johnson & Johnson, Novartis International AG, The Kroger Co., Harmon Stores Inc., Great Lakes Wholesale Marketing and Sales Inc., Geri-Care Pharmaceuticals Corp., Fred's Inc., Dolgen Corporation, CVS Pharmacy Inc., American Sales Company, Cardinal Health Inc., Bedrock LLC, Greenbrier International Inc., Good Neighbor Pharmacy, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd.
Get The Full Global Antidiarrheals Market Report
Antidiarrheals Market Overview
The antidiarrheal drugs refer to drugs that relieve the frequent passing of a watery, loose stool, one of the symptoms of diarrhoea. According to their shared chemical or functional properties, antidiarrheal medications can generally be grouped into three groups: adsorbents, antimotility agents, and bacterial replacements (probiotics).
Antidiarrheals Global Market Report 2023 provides data on the global antidiarrheals market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The antidiarrheals market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.